| Oct 30 |
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
|
| Oct 28 |
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
|
| Sep 30 |
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
|
| Sep 16 |
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
|
| Jul 22 |
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
|
| Jul 17 |
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
|
| Jul 16 |
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
|
| Jun 20 |
Tharimmune announces $2.08M private placement
|
| Jun 10 |
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
|
| May 29 |
Tharimmune to Present at 2024 BIO International Convention
|
